`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF NEW JERSEY
`
`JAZZ PHARMACEUTICALS, INC.,
`
`Plaintiff,
`
`Honorable Esther Salas, U.S.D.J.
`Honorable Joseph A. Dickson, U.S.M.J.
`
`v.
`
`AMNEAL PHARMACEUTICALS LLC.
`
`Defendant.
`
`Civil Action No.
`2:13-00391-ES-JAD (consolidated)
`
`DOCU"MENTELECTRONICALLY
`FILED
`FILED UNDER SEAL
`
`!
`l
`
`THIS MATTER having been brought before the Court upon the Motion of Defendant
`
`Par Pharmaceutical, Inc. ("Par"), pursuant to Local Civil Rule 5.3(c), to Seal portions of its
`
`Brief in Support of Defendant Par Pharmaceutical, Inc.'s Motion for Judgment on the Pleadings
`
`as to U.S. Patent No. 8,772,306 under Rule 12(c) (ECF No. 245) and Exhibits E-H to the Frese
`
`Declaration submitted in support thereof. ("Par's 12(c) Motion and Exhibits"), in response to the
`
`complaint filed by Plaintiffs Jazz Pharmaceuticals, Inc. and Jazz Pharmaceuticals Ireland
`
`Limited (together "Plaintiffs" or "Jazz") with respect to the U.S. Patent No. 8,772,306; and the
`
`Court having considered the submissions of the parties in connection with the motion; and ~ej 0
`,
`- "
`4J ~'neg wt n•Vl1'<1 Co t'>te/.flftO I O.r S rru
`ff\dl S o'fhx;.f61!d (11Advslc4S o
`Court having considered the factors contained in L. Civ. R. 5.3(c)(2Kthe ourt ~akes the (ect=Jl/0 , ;,.<tc.-J.} t.l · lt1to~
`.. ~H-IW'c..\
`+ht 5-..w "1er111tt hrre.fert1tce'
`following-Findings of Fact and Conclusions of Law:
`,
`j
`
`• Par's 12(c) Motion and Exhibits contain confidential technical and business
`
`information that has been designated as "HIGHLY CONFIDENTIAL-SUBJECT
`
`TO DISCOVERY CONFIDENTIALITY ORDER" by Par under the Discovery
`
`Confidentiality Order entered in this action (ECF No. 144);
`
`• Par has a legitimate interest in protecting the confidentiality of its trade secret
`
`
`
`t-
`
`Case 2:13-cv-00391-ES-JAD Document 291 Filed 05/17/16 Page 2 of 3 PageID: 5414
`
`and other confidential research, development, commercial, and technical
`
`information;
`
`• Public disclosure of Par's information would cause Par significant harm because
`
`public disclosure of this trade secret and other confidential research,
`
`development, commercial, and technical information would provide the public
`
`insight into the business and operations of Par, its processes in considering and
`
`developing its proprietary technology, and would give competitors an unfair
`
`advantage;
`
`• Sealing such materials is the least restrictive alternative because it only includes
`
`information Par has identified and designated as "HIGHLY CONFIDENTIAL-
`
`SUBJECT TO DISCOVERY CONFIDENTIALITY ORDER" in this action.
`
`Therefore, the Court having found that there are legitimate public and private interests
`&
`which warrant the relief sought, IT IS on this~ -
`
`day of " " " \ , 2016,
`
`ORDERED that Defendant Par Pharmaceutical, Inc.'s Motion to Seal (ECF No. 246) is
`
`hereby GRANTED; and it is further
`
`ORDERED that the unredacted Brief in Support of Defendant Par Pharmaceutical, Inc.'s
`
`Motion for Judgment on the Pleadings as to U.S. Patent No. 8,772,306 under Rule 12(c) (ECF
`E-1-t ~
`) the Frese Declaration submitted in support thereof shall be sealed
`
`No. 245) and Exhibits
`
`and maintained under seal by the Court; and it is further
`
`ORDERED that the Clerk of the Court shall maintain on the docket a public copy of the
`
`Brief in Support of Defendant Par Pharmaceutical, Inc.' s Motion for Judgment on the Pleadings
`
`as to U.S. Patent No. 8,772,306 under Rule 12(c) redacted as consistent with this Order, which
`
`Par shall prepare and file within one week from this Order.
`
`2
`
`l
`r
`I
`
`j
`1
`
`I t
`
`i:.
`
`
`
`Case 2:13-cv-00391-ES-JAD Document 291 Filed 05/17/16 Page 3 of 3 PageID: 5415
`
`Q~
`HONOB~OSEPH A. DICKSON """-=
`
`UNITED STATES MAGISTRATE JUDGE
`
`r L
`I
`l
`
`! ' f'
`' j.
`'
`
`3
`
`